Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4000422 | Urologic Oncology: Seminars and Original Investigations | 2012 | 6 Pages |
Abstract
DCA indicate that for very low prevalence conditions such as LNI (1.2%), decision models are not useful. For low prevalence rates such as SVI, the use of different versions of the Partin Tables does not translate into meaningful net gains differences. Finally, for intermediate prevalence conditions such as EPE (18%), despite apparent performance differences, the net benefit differences were also marginal. In consequence, the current analysis could not confirm an important benefit from the use of the Partin Tables and it could not identify a clearly better version of any of the 3 available iterations.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Herbert M.D., Maxine M.D., Hendrik M.D., Karl M.D., Pierre M.D.,